Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer

Molecular Cancer Research

Volumn 11, Issue 1, 2013, Pages 62-73

  Kim, Jeong Kyu ^a   Noh, Ji Heon ^a   Eun, Jung Woo ^a   Jung, Kwang Hwa ^a   Bae, Hyun Jin ^a   Shen, Qingyu ^a   Kim, Min Gyu ^a   Chang, Young Gyoon ^a   Kim, Seung Jin ^a   Park, Won Sang ^a   Lee, Jung Young ^a   Borlak, Jürgen ^b   Nam, Suk Woo ^a  

^a The Catholic University of Korea   (South Korea)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; HISTONE DEACETYLASE 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE IDENTIFICATION; GENE TARGETING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 2; HUMANS; MICE; MICE, NUDE; NIH 3T3 CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TRANSFECTION;

EID: 84873028037     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0332     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108.
2. Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010;10:403-14: Erratum in: Nat Rev Cancer. 2010 Aug;(8):593.
3. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007;13:470-6.
4. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
5. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26:5420-32.
6. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett 2009;277:8-21.
7. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007;26:5310-8.
8. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as antineoplastic agents. Cancer Lett 2009;280:192-200.
9. Kramer OH. HDAC2: a critical factor in health and disease. Trends Pharmacol Sci 2009;30:647-55.
10. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005;113:264-8.
11. Noh JH, Eun JW, Ryu SY, Jung KH, Kim JK, Lee SH, et al. Increased expression of histone deacetylase2 is found in human hepatocellular carconoma. Mol Cell Toxicol 2006;2:166-9.
12. Baur AS, Shaw P, Burri N, Delacretaz F, Bosman FT, Chaubert P. Frequent methylation silencing of p15(INK4b) (MTS2) and p16 (INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 1999;94: 1773-81.
13. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008;9:139-48.
14. Kim H, Kim YH, Kim SE, Kim NG, Noh SH. Concerted promoter hypermethylation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability. J Pathol 2003;200: 23-31.
15. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2004;101:18030-5.
16. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009;280:168-76.
17. Hrzenjak A, Moinfar F, Kremser ML, Strohmeier B, Staber PB, Zatloukal K, et al. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells. Mol Cancer Ther 2006;5:2203-10.
18. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404.
19. Kaler P, Sasazuki T, Shirasawa S, Augenlicht L, Klampfer L. HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity. Exp Cell Res 2008;314: 1507-18.
20. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004;5:455-63.
21. Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell 2004; 5:121-5.
22. Noh JH, Jung KH, Kim JK, Eun JW, Bae HJ, Xie HJ, et al. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One 2011;6:e28103.
23. Fritsche P, Seidler B, Schuler S, Schnieke A, Gottlicher M, Schmid RM, et al. HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut 2009;58: 1399-409.
24. Hanigan CL, Van Engeland M, De Bruine AP, Wouters KA, Weijenberg MP, Eshleman JR, et al. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. Gastroenterology 2008;135:1654-64 e2.
25. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005;122:927-39.